Advertisement

Sulforhodamine B Assay and Chemosensitivity

  • Wieland Voigt
Protocol
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 110)

Abstract

The sulforhodamine B (SRB) assay was developed by Skehan and colleagues to measure drug-induced cytotoxicity and cell proliferation for large-scale drug-screening applications. Its principle is based on the ability of the protein dye sulforhodamine B to bind electrostatically and pH dependent on protein basic amino acid residues of trichloroacetic acid-fixed cells. Under mild acidic conditions it binds to and under mild basic conditions it can be extracted from cells and solubilized for measurement. Results of the SRB assay were linear with cell number and cellular protein measured at cellular densities ranging from 1 to 200‰ of confluence. Its sensitivity is comparable with that of several fluorescence assays and superior to that of Lowry or Bradford. The signal-to-noise ratio is favorable and the resolution is 1000-2000 cells/well. It performed similarly compared to other cytotoxicity assays such as MTT or clonogenic assay. The SRB assay possesses a colorimetric end point and is nondestructive and indefinitely stable. These practical advances make the SRB assay an appropriate and sensitive assay to measure drug-induced cytotoxicity even at large-scale application.

Key Words

Sulforhodamine B trichloroacetic acid optimal cell number cytotoxicity 

References

  1. 1.
    Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107–1112.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82, 1113–1118.PubMedCrossRefGoogle Scholar
  3. 3.
    Perez, R. P., Godwin, A. K., Handel, L. M., and Hamilton, T. C. (1993) A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur. J. Cancer 29A, 395–399.PubMedCrossRefGoogle Scholar
  4. 4.
    Griffon, G., Merlin, J. L., and Marchal, C. (1995) Comparison of sulforhodamine B, tetrazolium and clonogenic assays for in vitro radiosensitivity testing in human ovarian cell lines. Anticancer Drugs 6, 115–123.PubMedCrossRefGoogle Scholar
  5. 5.
    Keepers, Y. P., Pizao, P. E., Peters, G. J., van Ark-Otte, J., Winograd, B., and Pinedo, H. M. (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur. J. Cancer 27, 897–900.PubMedCrossRefGoogle Scholar
  6. 6.
    Hodes, L., Paull, K., Koutsoukos, A., and Rubinstein, L. (1992) Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel. J. Biopharm. Stat. 2, 31–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Voigt, W., Bulankin, A., Muller, T., Schoeber, C., Grothey, A., Hoang-Vu, C., and Schmoll, H. J. (2000) Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin. Cancer Res. 6, 2087–2093.PubMedGoogle Scholar
  8. 8.
    Papazisis, K. T., Geromichalos, G. D., Dimitriadis, K. A., and Kortsaris, A. H. (1997) Optimization of the sulforhodamine B colorimetric assay. J. Immunol. Methods 208, 151–158.PubMedCrossRefGoogle Scholar
  9. 9.
    Berenbaum, M. C. (1989) What is synergy? Pharmacol. Rev. 41, 93–141.PubMedGoogle Scholar
  10. 10.
    Greco, W. R., Bravo, G., and Parsons, J. C. (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331–385.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Wieland Voigt
    • 1
  1. 1.Klinik fūr Innere Medizin IV-Martin Luther Universitāt HalleHalle/SaaleGermany

Personalised recommendations